The phase 1/2 ReFocus trial evaluated RLY-4008, a selective FGFR2 inhibitor that can target FGFR resistance mutations, in CCA patients with FGFR2 fusions or FGFR2 rearrangements who did not receive FGFR inhibitors before. The gene discussed is FGFR2; the disease is cholangiocarcinoma.